Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules…
Fermenta Announces Granting of CEP by EDQM for VITADEE 100 SD, Enabling Accelerated Global Growth
THANE, India, July 30, 2025 /PRNewswire/ --Â Fermenta Biotech Limited ("Fermenta"), a pioneer…
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a…
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to…
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
 Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…